Jason Riley is currently the General Manager of Ultra-Rare Medicines at Amgen, following the acquisition of Horizon Therapeutics in October 2023. Previously, Jason served as Group Vice President of the Rare Disease Business Unit at Horizon from 2020 to 2023, as well as Vice President and Executive Director within the Orphan Business Unit and Metabolic Diseases respectively. Earlier in their career, Jason held positions at Lundbeck as Associate Director and Senior Product Manager in Epilepsy Marketing. Jason earned a B.A. from the University of Nebraska between 1992 and 1996.
This person is not in the org chart
This person is not in any teams
This person is not in any offices